Compare GTY & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTY | ADMA |
|---|---|---|
| Founded | 1955 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1998 | 2012 |
| Metric | GTY | ADMA |
|---|---|---|
| Price | $32.61 | $9.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $32.60 | $25.67 |
| AVG Volume (30 Days) | 370.3K | ★ 1.7M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.92% | N/A |
| EPS Growth | ★ 8.00 | N/A |
| EPS | ★ 0.79 | 0.35 |
| Revenue | ★ $221,727,000.00 | $42,219,783.00 |
| Revenue This Year | $9.39 | $27.46 |
| Revenue Next Year | $7.83 | $22.11 |
| P/E Ratio | $41.18 | ★ $27.46 |
| Revenue Growth | 9.02 | ★ 43.85 |
| 52 Week Low | $25.39 | $7.21 |
| 52 Week High | $36.83 | $20.46 |
| Indicator | GTY | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 53.66 |
| Support Level | $32.56 | $9.23 |
| Resistance Level | $33.90 | $10.24 |
| Average True Range (ATR) | 0.50 | 0.27 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 32.45 | 38.89 |
Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.